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ABSTRACT 
Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has 
shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin 
deletion in Sost knockout mice (Sost-/-) causes high bone mass (HBM) similar to Sclerosteosis patients. 
Sost-/- mice have been shown to display an up to 300% increase in bone volume/total volume (BV/TV), 
relative to aged matched controls, and it has been postulated that the main source of skeletal Sclerostin is 
the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost-
/- mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the 
skeletal phenotypes of conditional Sost loss-of-function (SostiCOIN/iCOIN) mice with specific deletions in (1) 
the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) mid-stage osteoblasts 
and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre) and (4) hypertrophic chondrocytes 
and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in 
trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the 
amplitude of the HBM phenotype in the appendicular skeleton and the B cell defect described in the 
global knockout. Despite wildtype expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these 
mice also had a significant increase in bone mass in the vertebrae, but the Sclerostin released in 
circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both 
Col1 and Dmp1 deletion resulted in a similar 80% significant increase in trabecular bone mass, but only 
Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several 
cell types within the Prx1-osteoprogenitor derived lineages contribute significant amounts of Sclerostin 
protein to the paracrine pool of Sost, in bone. This article is protected by copyright. All rights reserved 
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Introduction 
Sclerostin (Sost) is a secreted Wnt antagonist that primarily functions to negatively regulate bone 
formation by preventing the propagation of Wnt signaling through the low-density lipoprotein receptor-
related proteins (LRP4/5/6 Wnt co-receptors) in osteoblasts, pre-osteocytes, and osteocytes.(1,2) Patients 
carrying homozygous SOST null mutations (Sclerosteosis) display generalized high bone mass (HBM),(3,4) 
a phenotype that is recapitulated in Sost knockout mice (Sost-/-).(5,6)  Conversely, overexpression of SOST 
in transgenic mice (SOSTtg) results in osteopenia.(7) Shortly after the gene responsible for Sclerosteosis 
was cloned, SOST transcripts were reported in bone, bone marrow, cartilage, kidney, liver, lung, heart and 
pancreas(3,4), however, histological examination determined that the osteocytes within cortical and 
trabecular bone were a dominant source of sclerostin.(8,9) These observations support the hypothesis that 
the HBM phenotype in both patients and mice is due to sclerostin deficiency in osteocytes, and that 
sclerostin acts in a paracrine manner.(10)  
 More recent reports have provided new evidence that sclerostin may also act in an endocrine 
manner. Sclerostin serum levels were found to correlate with bone phenotypes, and several groups have 
shown that serum sclerostin levels are elevated in post-menopausal compared to pre-menopausal 
women.(11-13) Estrogen treatment administered to post-menopausal women significantly decreased serum 
sclerostin and mRNA levels in bone biopsies compared to untreated post-menopausal women(13-15), 
suggesting that estrogen may function to inhibit Sost expression/production.(13,16) Similarly, an increase in 
SOST serum levels were documented for aging men and women.(13)  
Sclerostin serum levels are affected by age, gender, hormone and disease status, suggesting that 
sclerostin serum levels could impact bone physiology. Osteocytes are the likely source of most of the 
circulating sclerostin found in serum.  Thus, all of the above mentioned sclerostin-modulating factors 
could control sclerostin transcriptionally or post-transcriptionally, in bone. Another unresolved issue is 
whether bone-associated cell types other than osteocytes also contribute to the sclerostin protein pool 
locally and systemically, including osteoblasts, osteoclasts, bone lining cells, mesenchymal stem cells or 
other progenitors along the osteoblastic- and chondrogenic- lineages. To understand the cell-type specific 
contributions to the HBM phenotype described in Sost-/- mice, as well as to address the endocrine and 
paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-
function (SostiCOIN/iCOIN) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre-driven 
recombination) which targets osteoprogenitors and their progeny; (2) mid-stage osteoblasts and their 
progenitors (Col2.3-Cre-driven recombination); (3) early-stage osteocytes (Dmp1-Cre-driven 
recombination) and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre).  
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We were particularly interested in determining whether any of these mice phenocopy the global Sost 
deletion. Here we show that conditional deletion of Sost in Prx1-expressing cells recapitulates the global 
high bone mass phenotype of Sost-/-, resulting in ~250% more bone, in the femur. In contrast, both Col1- 
and Dmp1-specific deletions of Sost induced a significant but milder increase in bone formation, only 
30% that of Sost-/-, or ~80% more bone that wildtype (WT) controls. The vertebrae of Prx1-Cre deleted 
Sost mice also displayed a significant 50% increase in bone mass, suggesting that limb-bone derived 
sclerostin contributes significantly to the serum pool of sclerostin that normally suppresses bone 
formation in the spine.  Moreover, the sclerostin produced in the axial skeleton (i.e., in the skeletal tissues 
that avoid Prx1-Cre-mediated recombination) is too dilute in the circulation to impair bone formation 
rates in the appendicular skeleton, where the Sost gene is recombined. 
In addition, the relationships and interactions between the diverse cell types within the bone and 
their reciprocal effects on each other’s cell fate decisions have become a focus of intense research, with 
clinical applications to improve bone fracture healing, prevent age-related bone loss and immune 
deficiencies.  A significant knowledge gap exists as to the contribution of different osteolineage cells to 
the differentiation, proliferation, and long-term survival of B lymphocytes in the bone marrow (BM).  In 
global sclerostin knockout (Sost-/-) mice, we previously uncovered a cell-extrinsic requirement for 
sclerostin on B lymphocyte development(17).  Similar to mice with global Sost deletion, the total bone 
marrow cellularity in the femurs and tibiae was significantly reduced when Sost was deleted from Prx1-
expressing cells. However, B lymphocyte development was differentially affected by Sost deletion in the 
Prx1-, Col1- and Dmp1- expressing cells, suggesting that a specific population of sclerostin expressing 
cells in the bone influences B cell development and function.  
 
Material and Methods 
Experimental Animals 
Mice with C57Bl/6 background were used in this study. Sost conditional knockout (SostiCOIN/iCOIN) mice 
were generated by inserting an inverted GFP cassette, flanked by lox66 and lox71 sequences, in the intron 
of the Sost gene as previously described.(18) Female mice with Cre under the Prx1 promoter [B6.Cg-
Tg(Prrx1-cre)1Cjt/J], Col1 promoter [Tg(Col1a1-cre)2Bek], Dmp1 promoter [B6N.FVB-Tg(Dmp1-
cre)1Jqfe/BwdJ], or ColX promoter [Tg(Col10a1-cre)1421Vdm] were mated to SostiCOIN/iCOIN male mice 
to generate conditional mutations in SostiCOIN/iCOIN; Prx1-Cre, SostiCOIN/iCOIN; Col1-Cre, SostiCOIN/iCOIN; 
Dmp1-Cre and SostiCOIN/iCOIN; ColX-Cre mice, respectively. Genotyping was completed by PCR. At 16 
weeks of age, bones were dissected and processed for micro-computed tomography (µCT), RNA, 
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histology and immunofluorescence (IF). All animal work was IACUC-approved and performed at 
Lawrence Livermore National Laboratory or UC Merced in AAALAC-accredited facilities.  
Immunofluorescent Staining 
Femur and lumbar vertebrae were collected at 16 weeks of age were fixed, dehydrated, embedded and 
sectioned as previously described.(5) For immunofluorescence, Trypsin/EDTA was used for antigen 
retrieval for 25 minutes at 37°C. Primary antibodies: Anti-SOST (R&D, AF1589), Anti-GFP (Abcam, 
ab13970) and Anti-activated β-catenin (Millipore, Billerica, MA, USA) were used and incubated 
overnight at room temperature as previously described(19). Negative control slides were incubated with 
secondary antibody-only.  Stained slides were mounted with Prolong Gold with DAPI (Molecular 
Probes). ImagePro Plus V7.0 Software and a QIClick CCD camera were used for imaging and photo 
editing.  
 
Micro-computed tomography 
4th lumbar vertebrae and whole femora were collected and fixed for 48 hrs in 10% neutral buffered 
formalin, then stored in 70% EtOH at 4°C until scanning.  The entire vertebra and the distal 60% of the 
femur were scanned on a Scanco uCT-35 specimen scanner using 60 kVp, 180 mA, 750 ms integration 
time, and 10 µm voxel size(20).  The entire cancellous region of the lumbar vertebra within 100 um of the 
endplates was isolated by manual analysis and included in the analysis.  For the distal femur metaphysis, a 
2-mm region of secondary spongiosa was isolated by manual analysis.  The region of interest began 1 mm
proximal to the distal growth plate and extended proximally for 2 mm.  Prior to scanning, the total length 
of each femur was measured with digital calipers; these measurements were used to identify the mid-
diaphysis slice in each femur CT scan by taking in to account slice thickness (10 µm) and counting up in 
slices from the distal tip of the condyles until the calculated midshaft was reached.  The central 20 slices 
at midshaft were analyzed for cortical properties.   
 
Western Blot and Elisa 
Femur and lumbar vertebrae were collected from 12-16 week old aged matched mice, frozen in liquid 
nitrogen and stored at -80ºC until extraction. The bones were homogenized in 500µl of 
radioimmunoprecipitation assay buffer with appropriate volume of protease inhibitor cocktail (Sigma) at 
1ml/20g tissue then incubated on ice for 20 minutes prior to centrifugation at 18,000g for 20 minutes at 
4ºC. The protein lysate supernatant was then quantified using BCA assay (Pierce) and stored at -80C. 
SDS-PAGE was performed with equal quantities of total protein per sample on Nupage protein gels 
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(ThermoFisher). Protein was then blotted onto a PVDF membrane (Licor) for western blot analysis. 
Membranes were probed with primary antibodies specific for Sost (AF1589, R&D Systems) and β-actin 
(926-42210, Licor) followed by IRDye 800CW donkey anti-goat and IRDye 680RD donkey anti-rabbit 
secondary antibodies. Membranes were then imaged using Licor Odyssey FC imaging system. Mouse 
sclerostin (ALPCO, 41-SCLMS-E01), Rankl (R&D Systems Cat#MTR00) and Ctx-1 ELISA kits 
(RatLaps EIA CTX-1 Cat# AC-06F1) were used according to the manufacturer's instructions (1:10 
dilution for sclerostin and 1:1 dilution for Rankl and Ctx-1) to measure serum levels as previously 
described (N=3-4 per group) (21). 
 
Bone Marrow Harvests 
Mice were euthanized by CO2 inhalation followed by cervical dislocation.  Whole legs were dissected and 
muscles were removed.  Bones were crushed with a mortar and pestle in Medium 199 containing 2% fetal 
calf serum (M199+) in order to release the bone marrow. BM cells were rinsed away from the bone chips 
with PBS and collected into 15 ml conical tubes, resuspended by trituration and filtered through 70 
micron nylon mesh squares into sterile tubes.  Cells were next washed with M199+ and centrifuged at 
1500 rpm at 4°C for 5 minutes, after which cell pellets were resuspended and treated with ACK Lysis 
Buffer to remove erythrocytes.  The ACK-treated cells were washed, resuspended in M199+ and total cell 
counts were obtained using a hemocytometer and Trypan Blue staining to exclude dead cells.   
 
Analysis of Hematopoietic Cell Lineages by Flow Cytometry 
The following antibodies were purchased from eBioscience or Biolegend:  CD45 (30F11)-FITC, CD19 
(6D5)-PE, GR1 (RB6-8C3)-PECy7, CD3 (145-2C11)-APC, CD11b (M1/70)-biotin, purified FcBlock 
CD16/32 (90), CD25 (PC61)-FITC, BP1 (Ly51/6C3)-PE, B220 (RA3-6B2)-PECy7, CD117 (2B8)-APC, 
Rat IgG2a-PE, kappa isotype control, CD19 (6D5)-FITC, CD43 (1B11)-PE, IgM-(eb121-15F9)-
eFluor450, IgM (RMM01)-Brilliant Violet (BV) 421, IgD (11-26c.2a)- BV510.  1-2x106 cells per sample 
were stained in 96-well V-bottom plates (Nunc, Inc) with their designated antibody cocktail and incubated 
for at least 15 min at 4ºC before washing with FACS buffer and centrifuging at 2000 rpm at 4ºC for 3 
min.  Supernatants were removed from the plates and cells incubated with streptavidin-Pacific Blue to 
develop biotinylated CD11b-stained cells when required.  Cell viability was assessed using DAPI or 
propidium iodide (PI) solution at a final concentration of 0.2 μg/ml.  Cells were acquired on a Becton 
Dickinson LSR II and flow cytometric analysis was performed using FlowJo software. A
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Statistics 
All data were expressed as the mean + standard deviation. For µCT, and flow cytometry results, statistical 
analysis was done using Student’s T-test with a two-tailed distribution, with two-sample equal variance 
(homoscedastic test) and one-way ANOVA with multiple comparisons. For all tests, p< 0.05 was 
considered statistically significant.   
 
RESULTS 
Dmp1-Cre Deletion Pattern Most Closely Recapitulates Endogenous Sost Expression, in Bone 
Conditional deletion of Sost from different cell populations allows us to determine cell-specific 
contributions to bone metabolism as well as to distinguish local from systemic effects. Using a previously 
described Sost conditional loss-of-function by inversion allele (SostiCOIN/iCOIN),(18) we eliminated Sost 
expression in (i) the limb mesenchyme (Prx1-Cre);(22) (ii) osteoblasts (Col1-Cre)(23); and (iii) osteocytes 
(Dmp1-Cre).(24) Upon Cre-mediated recombination, the conditional Sost allele undergoes premature 
termination of the endogenous Sost transcript, while simultaneously activating eGFP in frame with Sost, 
allowing us to track endogenous Sost expression using eGFP in cells that are now sclerostin deficient.(18) 
Previously, it has been shown that a mouse of the SostiCOIN/LacZ; LacZNannog-Cre/+ genotype has high bone 
mass (HBM) indistinguishable from the global Sost knockout allele that replaces the Sost gene with the 
LacZ reporter (SostLacZ/LacZ; and referred to as Sost-/- in this manuscript).(5,18) Since the iCOIN-inverted 
allele allows us to visualize Sost deficient cells through the presence of eGFP, we first compared the 
eGFP expression in the bones of SostiCOIN/iCOIN; Prx1-Cre, SostiCOIN/iCOIN; Col1-Cre, SostiCOIN/iCOIN; Dmp1-
Cre to the endogenous Sost expression in the control SostiCOIN/iCOIN mice. 
Cortical bone expression of eGFP was highest in the osteocytes of Dmp1-Cre deleted mice, and 
punctate expression was also detected in the matrix, suggesting that the Sost-eGFP fusion protein is able 
to exit the osteocytes (Fig. 1A-D). Since eGFP is a membrane bound version, we speculate that this 
expression may be due to microvesicles shed by osteocytes. SostiCOIN/iCOIN; Col1-Cre deleted mice 
displayed the lowest expression levels in cortical osteocytes (Fig. 1C), suggesting that only a minority of 
embryonically labeled Col1-positive cell mature into osteocytes. In the trabecular region of the femurs, 
Dmp1-Cre mice also had the greatest expression; the expression was higher than the endogenous Sost 
expression (Fig 1A, D), suggesting that these cells are accumulating higher levels of Sost-eGFP than in 
the endogenous bone maybe due to retention of eGFP in the membrane (Fig. 1E-H). Similar to the cortical 
bone results, SostiCOIN/iCOIN; Col1-Cre mice also expressed eGFP in fewer trabecular osteocytes (Fig. 1G). 
The expression of eGFP in the vertebrae of SostiCOIN/iCOIN; Col1-Cre and SostiCOIN/iCOIN; Dmp1-Cre was 
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similar to that described above for the femoral trabeculae; however, consistent with its site of Cre 
recombinase expression, none of the SostiCOIN/iCOIN; Prx1-Cre mice did not express any eGFP in the 
vertebrae (Fig 1. I-L). Western blot analysis showed the highest Sost-eGFP and the lowest Sost 
expression in the SostiCOIN/iCOIN; Prx1-Cre femurs (Prx1), while no Sost-eGFP was detected in the 
vertebrae, consistent with Prx1-Cre site of expression in appendicular skeleton (Fig 1M). Sost serum 
levels were reduced by ~50% in Prx1-Cre mice, but no detectable Sost was measured in Dmp1-Cre and 
Col1-Cre mice (Fig 1N), this data suggests that Sost serum levels in Prx1-Cre mice is exclusively derived 
from the axial skeleton. 
 
Dmp1-Cre Deletion of Sost does not Recapitulate Sost-/- HBM Phenotype  
Originally, Sost was described as an osteocyte specific gene(25), and while in recent years Sost expression 
has been found in other organs and cell types of the skeleton(8), osteocytes do express a robust amount of 
Sclerostin (Fig.fig 1A, E, I), therefore we anticipated that Dmp1-Cre deletion of Sost would most closely 
resemble the HBM phenotype of Sost-/- mice.  At 16 weeks of age, both SostiCOIN/iCOIN; Col1-Cre and 
SostiCOIN/iCOIN; Dmp1-Cre mice showed a significant increase in femoral BV/TV (Fig 2B, C, E-G), 
however, both these values were about 1/3 of those determined for Sost-/- and SostiCOIN/iCOIN; Prx1-Cre 
mice, suggesting that both osteoblast- and osteocyte-specific deletion of Sost result in the same HBM 
phenotype (Fig 2G). Vertebral BV/TV was also significantly increased in SostiCOIN/iCOIN; Col1-Cre and 
SostiCOIN/iCOIN; Dmp1-Cre mice by 81% and 88%, respectively, or ~50% of HBM in Sost-/- (Fig 2G).  
 
Prx1-Cre Deletion Recapitulates Sost-/- High Bone Mass Phenotype, in the Femur 
To determine whether conditional ablation of Sost in the limb mesenchyme, mature osteoblasts or 
osteocytes is sufficient to recapitulate the HBM phenotype observed in the Sost-/- mice we also bred 
SostiCOIN/iCOIN mice to Prx1-Cre, in addition to Col1-Cre and Dmp1-Cre (Fig. 2 A–D). All conditional 
knockout mice were indistinguishable in size and weight from their same-sex Cre-negative control 
littermates. At 16 weeks of age, microscale computed tomography (μCT) analysis of distal femurs showed 
that trabecular bone volume fraction (BV/TV) in all conditional knockouts was significant higher than the 
Cre-negative controls (Fig. 2a-d, E); however only the SostiCOIN/iCOIN; Prx1-Cre mice had a BV/TV 
increase of 257% (Table 1), a value similar to that of age matched Sost-/-  mice (+221%; Table 2), whereas 
both SostiCOIN/iCOIN; Col1-Cre and SostiCOIN/iCOIN; Dmp1-Cre mice had BV/TV increases of 85% and 81%, 
respectively (Fig. 2G; Table 1).  
While SostiCOIN/iCOIN; Prx1-Cre femurs most closely resembled femurs from Sost-/- mice, there 
were several noted differences. While Sost-/- did not display a significant increase in trabecular number, 
A
cc
ep
te
d
  A
rt
ic
le
 
 
with only an 8% increase above wildtype, SostiCOIN/iCOIN; Prx1-Cre femurs had a significant 24.18% 
increase in trabecular number (Table 1, 2). Another significant difference was in the cortical values, 
where SostiCOIN/iCOIN; Prx1-Cre femurs did not display significant increases in either cortical bone volume 
but had a significant increase in cortical thickness; Sost-/- had a significant 69.98% increase in cortical 
bone volume and a 31% increase in cortical BV/TV (Table 1, 2). Furthermore, neither SostiCOIN/iCOIN; 
Dmp1-Cre nor SostiCOIN/iCOIN; Col1-Cre had a significant increase in cortical BV/TV despite a significant, 
but more modest increase in cortical bone volume (Table 1, 2). Lastly, cortical bone mineral density was 
unchanged in all conditional Sost mice, whereas Sost-/- mice had a significant 3.21% gain (p-value=0.05) 
in cortical BMD (Table 1, 2). Consistent with the bone phenotype, levels of β-catenin were highest in the 
Prx1-Cre cortical and trabecular regions of the femur (Sup Fig 1). 
 
Prx1-Cre Deletion Results in Increased Bone Formation, in the Vertebrae 
Prx1-Cre drives Cre recombinase expression in uncommitted mesenchymal cells that contribute to bone, 
cartilage, muscle, white and brown adipose tissues of the developing appendicular skeleton.  Cre is also 
expressed in portions of the skull, but absent from other parts of the axial skeleton.(22,26) If Sost is retained 
locally, we anticipated Prx1-Cre deletion to cause HBM in the appendicular skeleton and to maintain 
normal bone mass in the axial skeleton, where Sost expression remains unperturbed. Lumbar vertebrae 
µCT analysis between SostiCOIN/iCOIN; Prx1-Cre and age-matched SostiCOIN/iCOIN control mice uncovered a 
significant (55%) increase in BV/TV ratio, suggesting that lack of Sost in the appendicular skeleton 
positively affects bone formation in the vertebrae (Fig. 2aa, F, G, Table 1). While trabecular number was 
not different in SostiCOIN/iCOIN; Prx1-Cre than controls, the trabecular thickness was significantly elevated 
by 16%. In addition, the trabecular bone mineral content was elevated by 88%, half of the Sost-/- value. 
Interestingly, neither Col1-Cre nor Dmp1-Cre deletion of Sost resulted in BV/TV increases similar to 
those measured for Sost-/-; displaying 81% and 88% increase, about half of Sost values (Fig. 2bb, cc, dd, 
F, G; Table 1,2). 
 
Prx1-Cre Deletion of Sost Results in Reduced Bone Marrow Cellularity 
To determine which Sost-expressing osteolineage cell type is responsible for B lymphocyte support, we 
analyzed hematopoietic differentiation in mice lacking Sost specifically in osteoprogenitors/MSCs [Prx1-
Cre], osteoblasts [Col1a-Cre] and osteocytes [Dmp1-Cre].  Similar to the global Sost-/- mouse, 
SostiCOIN/iCOIN; Prx1-Cre mice displayed a significant reduction in total BM cellularity; however, deletion 
of Sost in osteoblasts and osteocytes had no effect (Fig. 3B).  We further examined the frequency (%) and 
absolute number of total CD19+ B cells, and observed that the % of CD19+ cells was slightly reduced 
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when Sost was deleted in osteoblasts and osteocytes (Fig. 3A, C), but the absolute numbers of CD19+ 
cells were significantly reduced in the SostiCOIN/iCOIN; Prx1-Cre and SostiCOIN/iCOIN; Col1-Cre mice only 
(Fig. 3D). 
The CD19+ B cell population in the BM contains a heterogeneous mixture of B cell progenitors, 
developing B cells and mature B cells, which can be distinguished by expression of B220 and diminishing 
levels of CD43 (Fig. 4A and Sup Fig. 2A and Hardy et al(27).  B220+ CD43high cells are B cell progenitors 
with low expression of surface IgM and IgD.  The B220+ CD43-intermediate (B220+ CD43int) population 
begin to express surface IgM and coexpression of IgD can be observed as cells progress to the B220+ 
CD43low population.  Finally, the B220+ CD43-negative (B220+ CD43neg) population is the most mature 
B cell population, displaying high levels of IgM and IgD.  In order to determine if the four specific B cell 
stages  and the transition from one stage to the next were differentially affected by Sost deletion in 
specific osteolineage cell types, we enumerated the % and absolute numbers of B cells within each 
B220/CD43 subset, and their expression of IgM and IgD receptors in the conditional Sost knockout 
mouse strains.   In the global Sost knofbmckout, knockout, a developmental block beginning at the pre-B 
stage (similar to Hardy Fractions B and C(27)) and all committed B cell stages were observed(17) with 
changes in both frequency and cell number.  Our analysis of the 
SostiCOIN/iCOIN; Prx1-Cre bone marrow showed an increase in the % of phenotypically mature B220+ 
CD43neg cells compared to no Cre controls (Fig. 4B).  In contrast, the % of B220+ CD43neg cells was 
significantly decreased in the SostiCOIN/iCOIN; Dmp1-Cre bone marrow.  This suggested that deletion of 
Sost in the MSCs resulted in expansion of mature B cells, whereas deletion of Sost in the osteocytes 
resulted in fewer mature B cells.  However, the absolute numbers of B220+ CD43neg cells were not 
affected (Sup Fig. 3).  Mature B cells should express high levels of IgM and IgD.  Examination of IgM 
and IgD expression in the mature B cells of the SostiCOIN/iCOIN; Prx1-Cre bone marrow revealed an 
abnormally high proportion of cells that lacked expression of both IgM and IgD (Fig. 4F and Sup Fig. 
2B).  In line with this, the SostiCOIN/iCOIN; Prx1-Cre mice displayed the lowest proportion of mature IgM+ 
IgD+ cells amongst the different mouse strains (Fig. 4F).  Closer examination of the immature B220+ 
CD43int subset showed a similar trend of higher % of IgM- IgD- and lower % of IgM+ IgDlow cells in the 
SostiCOIN/iCOIN; Prx1-Cre bone marrow (Fig. 4E).  These results indicate that deletion of Sost in the Prx1+ 
cells affects upregulation of IgM and IgD at the later stages of B cell maturation. 
We also observed changes in B cell maturation in the SostiCOIN/iCOIN; Col1-Cre bone marrow, but 
in contrast to the Prx1-Cre bone marrow, the progenitor and early stages of development were altered. 
Significantly higher proportions of IgM- IgD- cells were observed at the B220+ CD43high and B220+ 
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CD43int stages (Fig. 4C and 4D), as well as lower proportion IgM+ IgDlow cells.  This suggested that the 
progression of B cells from the progenitor to early stages of development was somewhat delayed, and 
could explain the increased proportion of immature B220+ CD43low cells in the SostiCOIN/iCOIN; Col1-Cre 
bone marrow (Fig. 4B) and lower % and number of IgM+ IgD+ cells within this subset compared to the 
other mouse strains (Fig. 4E and Sup Fig. 2C and 3C).  Despite these changes, the proportions and 
numbers of mature B220+ CD43neg were similar to no Cre controls (Fig. 4F and Sup Fig. 3D).  Results 
from analysis of B cell subsets using alternative staining strategies were consistent with these results (data 
not shown). B cell development in SostiCOIN/iCOIN; Dmp1-Cre bone marrow was not significantly altered at 
any stage (Fig. 4C-F). These data suggest that Prx1-Cre and Col1-Cre, but not Dmp1-Cre deletion 
removes sclerostin in a subtype of osteoprogenitors required for distinct stages of B cell development. 
 
ColX-Cre Deletion of Sost Results in High Bone Mass 
ColX-Cre drives Cre recombinase expression in hypertrophic chondrocytes, cells that recently have been 
shown to trans-differentiate into osteoblasts.(29,30) Using lineage tracing, it has been shown that ColX-
positive cells substantially participate in trabecular, endosteal and cortical bone formation.(29) To 
determine whether conditional ablation of Sost in these cells also affects bone mass we compared ColX-
Cre conditional knockouts to the Cre-negative littermates. Microcomputed tomography (μCT) analysis of 
distal femurs showed that SostiCOIN/iCOIN; ColX-Cre knockouts had a significant 37.57% increase in the 
femoral and a 22.71% increase in the vertebral trabecular bone volume fractions (BV/TV) relative to the 
Cre negative controls (Table 3). Cortical bone mineral content was slightly elevated, but no other cortical 
parameters were significantly different, suggesting that ColX-Cre ablates Sost from a unique population of 
osteoprogenitor cells that give rise to Sost positive cells, in the adult bone. LacZ staining of mice carrying 
a Sost-LacZ allele did not detect Sost/LacZ expression in the hypertrophic chondrocytes of neonatal mice 
(Sup Fig. 4C), suggesting that the high bone mass phenotype is due to a subpopulation of Sost deficient 
osteoblasts and osteocytes, primarily in the trabecular compartment. 
 
Discussion: 
Sost/sclerostin is highly expressed in the osteocyte population (Sup Fig4A, B), and thus it has been 
hypothesized that the phenotypes observed in bone and hematopoietic development when Sost is deleted 
were due to lack of Sost in the osteocytes.  Contrary to this assumption, Dmp1-Cre deletion did not 
recapitulate the global Sost phenotype, unlike Prx1-Cre which fully recapitulated the Sost global 
phenotype in the appendicular skeleton. This result can have several interpretations: either Dmp1-Cre is 
incapable of ablating the Sost allele in all Sost-expressing osteocytes, and the residual non-recombined 
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osteocytes express sufficient Sost to blunt the otherwise strong phenotype locally, or several distinct 
populations of cells in the bone express Sost, and all these cells are derived from Prx1-positive 
progenitors. The interpretation that other cell types in addition to osteocytes are important contributors to 
the local pool of Sclerostin protein in bone is further supported by the observation that Col1-Cre deletion 
of Sost also had a HBM phenotype, but significant differences were noted between Col1 and Dmp1 
deletions. For example, a significant difference was observed in the femoral cortical thickness, where 
Dmp1 deletion did not increase the cortical thickness, but both Col1 and Prx1 did, implying that a 
subpopulation of periosteal osteoblasts do express Sost and these cells could be a population of 
osteochondral progenitors as previously suggested by Quyang et al(31).  
 Since only Prx1-Cre deletion of Sost recapitulates the HBM phenotype of Sost global knockout, in 
the appendicular skeleton, we can conclude that the only Sost expression affecting bone mass is derived 
from descendants of Prx1-positive limb bud progenitors (Fig. 5). During embryonic development Prx1- 
positive mesenchymal stem cells (MSC) give rise to muscle, adipocyte and osteochondral progenitors, 
which are the predecessors of mature myocytes, adipocytes, chondrocytes, hypertrophic chondrocytes, 
osteoblasts and osteocytes. While endogenous Prx1 is also expressed in the vertebrae and is required for 
early events of skeletogenesis in multiple lineages(32), the Prx1-Cre transgene expresses Cre recombinase 
from a limb enhancer, therefore, the Cre expression is restricted to all limb bud MSC derived cells of the 
appendicular skeleton(22). Here we showed that Sost deletion in mature osteoblasts and their descendant 
(Col1-Cre) or mature osteocytes (Dmp1-Cre) elevate bone mass by 80%, respectively, while deletion in 
hypertrophic chondrocytes and their descendants (ColX-Cre) elevated trabecular bone mass by 37%. 
While all these individual alleles do have a significant HBM phenotype, none does, nor do they all 
cumulatively sum up to the HBM amplitude of Prx1-Cre or Sost-/- alleles (80%+80%+37.5% < 250% 
BV/TV; Tables 1-3), further strengthening the argument that additional Prx1-derived cells are responsible 
for Sost expression, in bone. The two lineages not represented in our collection of Cre alleles are the 
myogenic and the adipogenic lineages which cannot yet be excluded as contributors to both the HBM and 
the B cell phenotypes. Mining available microarrays and RNA-seq data sets did not identify significant 
transcript levels of Sost in other Prx-1 derived cell types, however, future improvements in cell 
purification methods followed by RNA-seq may identify subpopulations of cell expressing Sost. Sost 
expression has also been observed in the osteoclasts of aging mice(33); while we did not examine the 
phenotype of osteoclast-specific deletion of Sost, global Sost knockout, nor any of the conditional strains 
examined showed a significant change in markers of resorption (Sup Fig. 5). 
Herein, we have also presented data that emphasizes novel roles for sclerostin in MSCs and OBs 
which distinctly impact BM cellularity and B cell maturation, and we conclude that loss of Sost in mature 
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osteocytes does not play a major role in regulating B cell development.  Loss of Sost expression in Prx1-
positive MSCs and their descendants resulted in reduced BM cellularity, whereas this process was 
unaffected by Sost-deficiency in mature osteoblasts (Col1-Cre) and osteocytes (Dmp1-Cre).  Furthermore, 
MSC-specific depletion of Sost caused an accumulation of abnormal B cells with no or low expression of 
IgM and IgD receptors that otherwise appeared phenotypically mature.  The changes observed in the 
frequencies and the absolute numbers of B cell subsets did not follow the same patterns.  For example, the 
% of of progenitors, early, immature and mature B cell subsets increased or decreased amongst the 
different deleter strains, but their numbers were not significantly different among all groups (Fig. 4B and 
Sup Fig. 3).  This may stem from the fact that MSCs, osteoblasts, and osteocytes have a progenitor-
progeny relationship and it is likely that deletion of Sost in each cell type is not synchronized, so some 
MSCs may progress to the osteoblast stage before Sost deletion occurs and support B cell development 
normally.  Since total BM cellularity is decreased in the Prx1-Cre mice, one might expect that the cell 
number in all fractions would be proportionally decreased; however, only numbers of B220+ CD43int 
immature were significantly reduced when Sost was deleted in MSCs, indicating that immature B cells 
require normal Sost levels.  Our findings are consistent with recent work that demonstrated that MSCs and 
osteoblasts are important “niche cells” for early B cell development, with respect to their production of 
CXCL12(34,35).  CXCL12 expression is regulated by Wnt signaling in BM stromal cells in vitro.(36)  We 
observed diminished CXCL12 levels in non-hematopoietic cells of the bone in and correlated the 
diminished CXCL12 levels with the reduction in B cell development in the global Sost-/- mice.(17)  Our 
present results suggest that Sost specifically expressed in MSCs and osteoblasts regulate B cell 
development, but further analysis is required to determine if expression of CXCL12 and other Wnt target 
genes are altered in MSCs and osteoblasts in the Prx1-Cre and Col1-Cre Sost deleters. 
 Alternatively, it is possible that the B cell defect is indirect. Recently we have observed that bone 
marrow adiposity positively correlates with Sost expression levels, such that a mouse model of type I 
diabetes mellitus (T1DM) with elevated levels of Sost displayed enhanced bone marrow adiposity and 
this phenotype was rescued by Sost antibody treatment.(21) Also, a recent report has described Sclerostin 
as a promoter of adipogenic differentiation(37) suggesting that lack of Sost may impair adipogenesis. Bone 
marrow adipocytes can be lineage-traced using Prx1-Cre and Osx-Cre, in contrast to other adipocyte 
lineages(38), and the microenvironment in the bone marrow of aged mice appears to favor adipogenesis 
over osteogenesis in mesenchymal progenitor cells(39).  The relationship between adipocytes and immune 
cell development is a current area of research.  The transition of human common lymphocyte progenitors 
to the early pre-proB cell stages have been shown to be inhibited by a soluble factor produced by bone 
marrow adipocytes(40), and stem cell factor produced by Lepr+ BM adipocyte precursors is necessary for 
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the generation of B cells and other hematopoietic cells in mice(41). Based on these data, any impairment in 
adipogenesis by Sost depletion may be unrelated to the decrease in mature B cells we have observed in 
Sost-knockout mice. Nonetheless, it would worth exploring whether Sost affects B cell development by 
interfering with bone marrow adipogenesis. Our analysis of global Sost knockout mice showed significant 
decreases in the B cell precursors and immature subsets but this was not as dramatic in the SostiCOIN/iCOIN; 
Prx1-Cre mice, which suggests that there is another cell that expresses Sost that is important in supporting 
these early B cell subsets.   In contrast, Prx1+ and Col1+ Sost-expressing cells are critical for normal B 
cell maturation.   It remains to be determined whether the bone marrow adipocytes in these Sost-deficient 
mice are reduced or impaired in their function to support B cell maturation.  
Our analyses demonstrate that deletion of Sost in mature osteocytes does not significantly impair 
B lymphocyte development nor does it cause the HBM observed in the global Sost-/- therefore other cell 
types derived from Prx1-positive MSCs are critical in these processes.  Furthermore, we show that Prx1-
Cre deletion of Sost resulted in a significant increase in bone mass in the axial skeleton, where Sost alleles 
remain wildtype. This result suggests that Sost expressed in the vertebra is diluted out in the circulation, 
decreasing the net pool of Sost in the axial skeleton and contributing the increased BV/TV in this tissue, 
however, the vertebra derived Sost in circulation does not act in an endocrine fashion, leaving the 
appendicular skeleton unperturbed. These results indicate that Sost primarily acts locally in bone via 
paracrine secretion and that endocrine secretion of Sost from distant sites do not significantly impair bone 
mass. Since anti-sclerostin antibodies are likely to become a new therapy to build bone in osteoporosis 
patients, it is imperative to target these therapies to bone to avoid undesired side-effects in other tissues 
that may require Sost for their proper function, and to test whether these therapies leave B cell 
development unperturbed in these patients.  Our results suggest that if Sost-depletion by Sost antibodies is 
limited to osteocytes, possible side effects on B cell development and immunity could be avoided, but 
may elicit a more modest anabolic effect on bone mass.   
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Figure Legends: 
Fig. 1. Evaluating Efficiency of Sost conditional deletion in bone. Endogenous Sost protein expression 
in SostiCOIN/iCOIN was visualized in cortical and trabecular bone of the femur (A, E) and vertebrae (I) by 
immunohistochemistry and was consistent with previous wildtype expression of Sost (red) in mice (blue 
DAPI). Cre deletion of Sost allele activates eGFP, Sost expressing cells and carrying Sost deletion now 
express a Sost-eGFP fusion protein which is visualized in panels B, C, D, F, G, H, J, K, L in red; blue 
DAPI). Prx1-Cre deletion activated eGFP in Sost deficient cortical (B), and trabecular osteocytes (F) in 
the femur, but not in the vertebrae, where Prx1-Cre is not expressed (J). Col1-Cre deletion activated eGFP 
in Sost deficient cortical (C), and trabecular osteocytes (G) in the femur, and also in the osteocytes within 
the vertebrae (K). Dmp1-Cre deletion activated eGFP in Sost deficient cortical (D), and trabecular 
osteocytes (H) in the femur, and also in the osteocytes within the vertebrae (L). Western blot analysis (M) 
showed that most of Sost expression was removed in Prx1, Col1 and Dmp1 deleted femurs, but Sost 
expression persisted in the Prx1 vertebrae.  eGFP protein expression inversely correlated with the Sost 
expression (M). 
Fig. 2. Comparing Skeletal Phenotypes of Sost conditional mice to Sost-/- mice. MicroCT analysis of 
axial and appendicula skeleton of Prx1-Cre (A), Col1-Cre (B), Dmp1-Cre and Sost-/- (D) visually 
highlights increases in bone mass in both femurs (a, b, c, d) and vertebrae (aa, bb, cc, dd). Prx1-Cre 
deletes Sost in all MSC-derived cells in the appendicular skeleton only (A, red); Col1-Cre (B) and Dmp1-
Cre (C) delete Sost in osteoblast and osteocytes throughout the skeleton; global knockout deletes Sost in 
all cell types of the skeleton (D). Quantification of trabecular BV/TV finds all mice to have a significant 
increase in both the femoral (E) and vertebral (F) bone fractions, however, only Prx1-Cre mice had a % 
change in BV/TV comparable to Sost-/- (G). *p<0.05, both by ANOVA and t-test. 
Fig. 3.  Bone marrow cellularity and lymphocyte frequencies and cell numbers are differentially 
affected by the absence of Sost in specific osteolineage cell types.  A) Representative flow cytometry 
plots of CD19 (B cell) and CD3 (T cell) lineages in the bone marrow of no-Cre control and conditional 
Sost knockout mice (A); Total bone marrow cellularity (B); Frequencies of CD19+ cells out of total BM 
cells (C); Absolute numbers of CD19+ B cells in BM (D).  *p<0.05, **p<0.01, ***p<0.001 both by 
ANOVA and t-test, except in B, where comparison of control vs. Prx1-Cre by ANOVA showed p<0.01, 
and C, where comparison of control vs. Col1-Cre by ANOVA showed p<0.05.  
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Fig. 4.  Loss of Sost in MSCs and OBs differentially regulates earlier and later stages of B cell 
development in the bone marrow.  A) Schematic of B lineage maturation in the bone marrow, with cell 
surface markers for each maturation stage indicated.  B)  Stacked bar graph of mean frequencies + 
standard deviation of progenitor (pro-B/pre-B, black) early (light green), immature (grey) and mature 
(yellow) B cell stages, and  mean frequencies + standard deviation of IgM- IgD- (red), IgM+ IgDlow 
(blue), and IgM+ IgD+ (beige) in C) pro-B/pre-B, D) early, E) immature and F) mature B cells stages in 
control (no Cre), Prx1-Cre, Col1-Cre, and Dmp1-Cre conditional Sost knockout mice. *p<0.05, Student’s 
t-test.  Exact p-values for comparisons of interest that did not achieve p<0.05 are shown in the stacked bar
corresponding to the group. 
 
Fig. 5.  Cell types along the MSC/Prx1-Cre lineages. Prx1-Cre deletes early during differentiation and 
ablates Sost in all derived cells, this mouse fully recapitulates the Sost-/- phenotypes. Col1-Cre and Dmp1-
Cre ablate Sost in the osteoblast lineage, and both deletions result in similar phenotypes. ColX-Cre ablates 
Sost in the hypertrophic chondrocytes, and has the lowest increase in BM. 
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Supplementary Fig. 1. Activated β-catenin in conditional Sost knockout mice.  Cortical (A-F) and 
trabecular (a-f) regions of the femur were examined for -catenin expression in no Cre wildtype controls 
(A, a) global Sost knockout (B, b) and conditional knockouts SostiCOIN/iCOIN; Prx1-Cre (C, c), 
SostiCOIN/iCOIN; Col1-Cre (D, d), SostiCOIN/iCOIN; Dmp1-Cre (E, e) and SostiCOIN/iCOIN; ColX-Cre (F, f). bm 
bone marrow, t trabecular. 
 
Supplemental Fig. 2.  Examples of flow cytometry analysis of B cell maturation in conditional Sost 
knockout mice.  A) scheme of B cell maturation and flow cytometry “map” of the subsets in plots shown 
in B and C.  B) representative plots of bone marrow from a “no Cre” control and 2 SostiCOIN/iCOIN; Prx1-
Cre mice; C) representative plots from a “no Cre” control, and a SostiCOIN/iCOIN; Col1-Cre and a 
SostiCOIN/iCOIN; Dmp1-Cre mouse. 
 
Supplemental Fig. 3.  Absolute cell counts amongst B cell subsets in conditional Sost knockouts.  A) 
# of cells by maturation stage as defined by B220 and CD43 expression.  Analysis of IgM-IgD-, IgM+ 
IgDlow and IgM+ IgD+ cells within B) early, C) immature and D) mature stages of B cell development.  
No differences in cell counts were observed amongst the pro-B/pre-B subsets (data not shown).  *p<0.05, 
unpaired Student’s t-test. 
 
Supplementary Fig. 4. LacZ expression in Sost knockouts with LacZ knock-in. Sost-/- mice with the 
LacZ reporter, which were previously described(42), were collected and stained as previously described(8). 
Sost expression in adult was detected in the osteocytes within bone matrix in the calvaria (A), on the bone 
surface of the tibia and in a very small population within the bone marrow (which we can assume are 
osteo-progenitor or MSC cells) (B). Sost/LacZ was not expressed in hypertrophic chondrocytes in the 
growth plate (C) nor peripheral regions (D) in the humerus of neonates; ocy osteocytes. 
 
Supplementary Fig. 5. Examining Osteoclast Markers. Trabecular regions of 16-week old femurs from 
the global Sost knockout and conditional knockouts were examined by TRAP staining (A).  RNAseq of 
whole femurs from Sost-/- showed slightly elevated levels of Acp5 (TRAP) mRNA (B). Serum levels of 
RANKL (C) and CTX-1 (D) were also slightly elevated in Sost-/- relative to wildtype, but not statistically 
significant. Serum levels in the conditional mice were not significantly different than the Cre-negative 
controls, for each group.  A
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